Of them, the gut microbial metabolite butyrate has been reported to engage in the enhanced anti-PD-1 therapeutic efficacy through increasing the CD4+ and CD8+ T cell infiltration in the TME in the tumor-bearing mice humanized with the intestinal microbes from colorectal cancer (CRC) patients (62). The gene discussed is CD8A; the disease is neoplasm.